HemoCath Intelligent Heart Failure Monitoring Platform

HemoCath-guided heart failure management will soon become the standard of care – reducing hospital length of stay and rehospitalization – and improving patient quality of life.

• HemoCath is the NEXT GENERATION of pulmonary artery (PA) catheters

•  Substantially less invasive, more accurate and easier-to-use

•  Directly measures/monitors PAP and CVP in real-time

•  Communicating with patients’ mobile phone & secure cloud

•  Remote patient monitoring services (SaaS, AI)

•  Reducing hospital length of stay and rehospitalization for heart failure*

Pulmonary artery pressure (PAP)-guided heart failure diagnostic, therapy and monitoring have shown to reduce hospital length of stay and rehospitalization*

* CardioMEMS and CHAMPION clinical studies have shown that PAP-guided heart failure management reduces hospital length of stay by 42% and 30-day readmissions by 58% compared to the standard of care for patients with heart failure. See: PubMed.gov and Circ Heart Fail.

Problems Resolved

The two most important metrics for the treatment of heart failure are the pulmonary artery pressure (PAP) and the central venous pressure (CVP). Unfortunately, these two metrics are not easily available today. So, cardiologists use several indirect methods that are LATE and IMPRECISE (e.g. Edema, JVP, Lung sounds, BUN, Cr, BNP, Echo, X-ray). Or, they use medical devices that are TOO INVASIVE and RISKY (e.g. today’s PA catheters, CardioMEMS). Leading to suboptimal medication dosing, suboptimal treatment, longer hospital stay and 30-day rehospitalization.